We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

34 hedge funds and large institutions have $25.4M invested in SAB Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

5.58% less ownership

Funds ownership: 6.29% → 0.71% (-5.6%)

17% less funds holding

Funds holding: 41 → 34 (-7)

20% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 35

73% less capital invested

Capital invested by funds: $93.6M → $25.4M (-$68.1M)

Holders
34
Holders Change
-7
Holders Change %
-17.07%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
3
Reduced
3
Closed
35
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FPB
First PREMIER Bank
South Dakota
+$7.81M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$6.41M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.75M
4
RCM
Radcliffe Capital Management
Pennsylvania
+$1.86M
5
IFAM
Institutional & Family Asset Management
Colorado
+$686K

Top Sellers

Rank Fund Capital Flow
1
KIM
Karpus Investment Management
New York
-$10.4M
2
FTCM
Fir Tree Capital Management
New York
-$6.55M
3
KC
Kepos Capital
New York
-$6.3M
4
WRBC
W.R. Berkley Corp
Connecticut
-$5.5M
5
PC
Periscope Capital
Ontario, Canada
-$5.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Penserra Capital Management
California
$27K +$32.7K +349 New
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$16K +$18.4K +196 +4,900%
Osaic Holdings
28
Osaic Holdings
Arizona
$16K +$18.9K +201 New
Bank of America
29
Bank of America
North Carolina
$16K +$20.4K +217 New
TRCT
30
Tower Research Capital (TRC)
New York
$12K +$14.7K +157 New
Citigroup
31
Citigroup
New York
$10K +$12.1K +129 New
Rockefeller Capital Management
32
Rockefeller Capital Management
New York
$5K +$6.57K +70 New
Marshall Wace
33
Marshall Wace
United Kingdom
$3K +$4.69K +50 New
Daiwa Securities Group
34
Daiwa Securities Group
Japan
$1K +$1.22K +13 New
KIM
35
Karpus Investment Management
New York
– -$10.4M -103,623 Closed
FTCM
36
Fir Tree Capital Management
New York
– -$6.55M -64,976 Closed
KC
37
Kepos Capital
New York
– -$6.3M -62,500 Closed
WRBC
38
W.R. Berkley Corp
Connecticut
– -$5.5M -54,565 Closed
PC
39
Periscope Capital
Ontario, Canada
– -$5.34M -53,020 Closed
Hudson Bay Capital Management
40
Hudson Bay Capital Management
Connecticut
– -$5.04M -50,000 Closed
PAMP
41
Polar Asset Management Partners
Ontario, Canada
– -$5.04M -50,000 Closed
BCM
42
Basso Capital Management
Connecticut
– -$4.43M -43,948 Closed
ASM
43
ATW SPAC Management
New York
– -$4.03M -40,000 Closed
CH
44
CVI Holdings
Delaware
– -$3.53M -35,000 Closed
MF
45
Magnetar Financial
Illinois
– -$3.27M -32,412 Closed
MSU
46
Mizuho Securities USA
New York
– -$2.93M -29,448 Closed
HSBC Holdings
47
HSBC Holdings
United Kingdom
– -$2.77M -27,510 Closed
YCM
48
Yakira Capital Management
Connecticut
– -$2.53M -25,070 Closed
DKCM
49
Davidson Kempner Capital Management
New York
– -$2.01M -20,000 Closed
Millennium Management
50
Millennium Management
New York
– -$1.93M -19,131 Closed
1
2
3

SABS Hedge Fund Activity: Q4 2021 in Review

34 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2021, worth a combined $25.4M — down 73% from $93.6M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of SABS and 28 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was First PREMIER Bank, opening a new position worth an estimated $7.81M. The largest seller was Karpus Investment Management, exiting entirely with an estimated $10.4M sold.

  • 34 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2021, down from 41 in Q3 2021.
  • Funds reported $25.4M of SAB Biotherapeutics stock for Q4 2021, down 73% quarter-over-quarter.
  • 28 funds opened new SAB Biotherapeutics positions in Q4 2021 and 35 closed out, a net change of -7 holders.
  • The largest SAB Biotherapeutics buyer in Q4 2021 was First PREMIER Bank, an estimated $7.81M added.
  • The largest SAB Biotherapeutics seller in Q4 2021 was Karpus Investment Management, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2021.